Professor Michael Green to present at ABA’s Toxic Torts & Environmental Law Committee annual meeting April 6-8
Research | Comments Off
Office of Communications and Public Relations
February 21, 2017
Professor Michael Green will present at the Toxic Torts & Environmental Law Committee’s 26th Annual Spring CLE Meeting, sponsored by the American Bar Association (ABA) on April 6-8, 2017, in Phoenix, Arizona.
Professor Green will participate on the first panel, “Causation: To Infinity and Beyond!,” on Saturday, April 8. According to the event website, the panel description is as follows: “Science continues to refine and confuse our ability to prove, or disprove, the essential question, causation. This panel of experts will discuss developments in the science of epidemiology and genetics and how they can, or can’t, be used in the courtroom.
“The panel will address topics such as clean and sustainable energy, chemical exposure, the rise of talc litigation and causation issues in environmental and tort cases.”
Professor Green is a co-author of National Academy of Sciences’ module on Scientific Evidence of Causation, has co-authored a chapter in the Federal Judicial Center’s Reference Manual on Scientific Evidence and covered the legal aspects of this issue in the Third Restatement of Torts, for which he was a Co-Reporter.
Other panelists include James McCluskey, MD/PhD, professor at the University of South Florida; Gary Marchant, PhD, professor of law at Arizona State University’s Center for Law, Science & Innovation; Howard Sandler of Sandler Occupational Medicine in New York; and Kirk Hartley, a Chicago lawyer with more than 30 years of experience in mass torts and several in various “omics” and cancer.
“My personal view is our panel has lots of expertise relevant to helping all sides see the need to get ready to deal with some serious possible stumbling blocks regarding the quality (or not) of the ‘low dose exposure histories’ of persons reported on in medical literature about germ line mutations and cancer,” Hartley writes. “The high dose exposure cases are relatively easy, but that’s not the case for ‘low dose’ cases involving genetically variable humans investigated by researchers who know little or nothing about the real world of products and use.”